Improving birth dose coverage of hepatitis B vaccine

Bulletin of the World Health Organization

Volumn 84, Issue 1, 2006, Pages 65-71

  Hipgrave, David B ^a   Maynard, James E ^b   Biggs, Beverley Ann ^c  

^a UNICEF   (United States)

^b Prog Appropriate Technol Hlth   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Drug stability (source: MeSH, NLM); Drug storage methods; Hepatitis B vaccines supply and distribution

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE;

CHILD HEALTH; DEVELOPING WORLD; HEPATITIS; VACCINATION;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; CRYOPRESERVATION; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG STORAGE; FEASIBILITY STUDY; HEALTH CARE POLICY; HEPATITIS B; HUMAN; LABORATORY TEST; MONITOR; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RURAL AREA; THERMAL EXPOSURE; THERMOSTABILITY; UNSPECIFIED SIDE EFFECT;

DISEASE TRANSMISSION, VERTICAL; DRUG STORAGE; HEPATITIS B; HUMANS; INFANT, NEWBORN; VIRAL HEPATITIS VACCINES;

HEPATITIS B VIRUS;

EID: 31444447157     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.04.017426     Document Type: Review

References (28)

1. Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain): Studies on active immunization. JAMA 1971;217:41-5.
2. Muraskin W. The war against hepatitis B: a history of the International Task Force on Hepatitis B Immunization. Philadelphia: University of Pennsylvania Press; 1995.
3. Hilleman MR. Plasma-derived hepatitis B vaccine: a breakthrough in preventive medicine. In: Ellis RW, editor. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker Inc; 1993. p. 17-40.
4. Hipgrave DB, Nguyen TV, Vu MH, Hoang TL, Do TD,, Trung NT, et al. Hepatitis B infection in rural Vietnam and the implications for a national program of infant immunisation. Am J Trop Med Hyg 2003;69:288-94.
5. Department of Vaccines and Biologicals, World Health Organization. Introduction of hepatitis B vaccine into childhood immunization services. Geneva: WHO; 2001.
6. Department of Vaccines and Biologicals, World Health Organization. Getting started with vaccine vial monitors. Geneva, WHO; 2002.
7. Lifelines Technology. Effect of ambient UV light exposure on color development of HEATmarker Vaccine Vial Monitors (WMs). Morris Plains, New Jersey: Temptime Corporation; 2003.
8. Galazka A, Milstien J, Zaffram M. Thermostability of vaccines. Global programme on vaccines. Geneva: World Health Organization; 1998.
9. Ellis RW. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker Inc; 1993.
10. Anonymous. Hepatitis B vaccine delivery outside the cold chain: the Long An County, China example. Global Perspectives on Hepatitis 1991;2:3-4.
11. Word Health Organization/Expanded Programme on Immunization. Report of 1993 Technet Conference. Geneva: WHO; 1993.
12. Otto BF, Suarnawa IM, Stewart T, Nelson C, Ruff TA, Widjaza A, et al. At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. Vaccine 1999;18:498-502.
13. Sutanto A, Suarnawa IM, Nelson CM, Stewart T, Soewarso TI. Home delivery of heat-stable vaccines in Indonesia: outreach immunization with a prefilled, single-use injection device. Bull World Health Organ 1999;77:119-26.
14. Hipgrave DB, Huong VM, Tran TN, Long HT, Van NT, Dat DT, et al. Immunogenicity of a locally produced Hepatitis B vaccine with the birth dose stored outside the cold chain in rural Vietnam. Am J Trop Med Hyg. In press.
15. Just M, Berger R. Immunogenicity of a heat-treated recombinant DNA hepatitis B vaccine. Vaccine 1988;6:399-400.
16. Van Damme P, Cramm M, Safary A, Vandepapeliere P, Meheus A. Heat stability of a recombinant DNA hepatitis B vaccine. Vaccine 1992;10:366-7.
17. Averhoff F, Mahoney FJ, Coleman PJ, Schatz GC, Hurwitz E, Margolis HS. Immunogenicity of Hepatitis B vaccines. Implications for persons at occupational risk of Hepatitis B virus infection. Am J Prev Med 1998;15:1-8.
18. Grabiner F, Prusik T. Temperature control requirements for WM end-point determination. Morris Plains (NJ): Lifelines Technology Inc; 2002.
19. Department of Vaccines and Other Biologicals. Testing the correlation between vaccine vial monitor and vaccine potency. Geneva: World Health Organization, 1999.
20. Levin CE, Nelson C, Widjaya A, Moniaga V, Anwar C. Costs of hepatitis B vaccine in a prefilled syringe in Indonesia. Bull World Health Organ 2005; 83:456-61.
21. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993;253: 197-201.
22. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992-1000.
23. Mast E, Mahoney F, Kane M, Margolis H. Hepatitis B vaccine. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines, 4th ed. Philadelphia: WB Saunders Co; 299-337.
24. Department of Vaccines and Biologicals. The use of opened multidose vials of vaccine in subsequent immunization sessions. Geneva: World Health Organization; 2000.
25. Into Good Hands. United Nations Fund for Population Activities and University of Aberdeen. Available from: http://www.unfpa.org/publications/index. cfm (accessed 4 June 2005).
26. Nelson C, Wibisono H, Purwanto H, Mansyur I, Moniaga V, Widjaya A. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions. Bull World Health Organ 2004;82:99-105.
27. Biofarma vaccines. Available from: http://www.biofarma.co.id/vaccines.htm (accessed 12 October 2005).
28. Quiroga R, Halkyer P, Gil F, Nelson C, Kristensen D. A prefilled injection device for outreach tetanus immunization by Bolivian traditional birth attendants. Rev Panam Salud Publica 1998;4:20-5.